~~<i id='F826134832'><strike id='F826134832'><tt id='F826134832'><pre id='F826134832'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：leisure time 2025-09-29 22:36:58 - browse：1

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. But some in the industry worry about the unintended consequences of overreliance.

Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

When the American Society of Health-System Pharmacists surveyed its members this past summer, 59% said they increased purchases from compounders because of drug shortages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout Newsletter: Parkinson's study, Gilead, CG Oncology

knowledge

hotspot

focus

leisure time

focus

Lawenforcementvehiclessitonthefreewayaspro-PalestinianprotestersblockInterstate5northboundonJan.6ind

WSS

Biden calls for immediate release of Niger's president amid apparent coup

Flu vaccine reformulation won't be easy, manufacturers warn

CVS is on a mission to consolidate health care. Will it work?

Influencer to be charged after chaos erupts in New York City's Union Square

Influencer to be charged after chaos erupts in New York City's Union Square

My superpower is killing ticks

focus

hotspot

knowledge

What does generative AI mean for health care? We asked experts

Dog Aging Project founders on what lies ahead after losing funding

Peter Hotez and the public health issue of online harassment

HPV vaccine, cervical cancer study delivers historic results

Medical leaders decry Supreme Court decision on affirmative action

Inaction leaves children at risk from dangerous chemotherapy drug

Peter Hotez and the public health issue of online harassment

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Stem cell clinics for heart failure: buyer be wary

hotspot

There's an unseen cost to disruptive road

HPV vaccine, cervical cancer study delivers historic results

For BCIs, commercial hurdles may be bigger than scientific ones

Cardiologists urge adding sexual orientation, gender identity to health records

Humana, CVS hope to turn members into patients at clinics

Update the Apgar Score to remove skin color

focus

leisure time

focus

focus